Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Bergqvist

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
Cancer Research|January 8, 2011
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapiesDana D Hu-Lowe, Enhong Chen, Lianglin Zhang, et al.
Journal of Medicinal Chemistry|August 12, 2016
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Journal of Medicinal Chemistry|December 13, 2016
Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The New England Journal of Medicine|December 25, 2015
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198FAlice T Shaw, Luc Friboulet, Ignaty Leshchiner, et al.
Cancer Research|January 8, 2011
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapiesDana D Hu-Lowe, Enhong Chen, Lianglin Zhang, et al.
Journal of Medicinal Chemistry|August 12, 2016
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Journal of Medicinal Chemistry|December 13, 2016
Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) InhibitorsPei-Pei Kung, Eugene Rui, Simon Bergqvist, et al.
Pageof 4